Clinical trial • Phase III • Other
vicadrostat for Healthy volunteer
Phase III trial of vicadrostat for Healthy volunteer. 45 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 08-01-2026
- First CTIS Authorization Date
- 20-03-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 45
Eligibility
Recruits 45 Vulnerable populations not selected; no consent or assent information provided..
- Vulnerable Population
- Vulnerable populations not selected; no consent or assent information provided.
Recruitment
- Planned Sample Size
- 45
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 45
Germany
- Earliest CTIS Part Ii Submission Date
- 27-02-2026
- Latest Decision Or Authorization Date
- 20-03-2026
- Processing Time Days
- 21
- Number Of Sites
- 1
- Number Of Participants
- 45
Sites
- Site Name
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Department Name
- Global Clinical Development & Operations
- Contact Person Name
- Nadine Beetz
- Contact Person Email
- nadine.beetz@boehringer-ingelheim.com
Sponsor
Primary sponsor
- Full Name
- Boehringer Ingelheim International GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- vicadrostat
Related trials
Other published trials that may interest you.